{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T16:55:47Z","timestamp":1789232147625,"version":"build-2803163510"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1097\/jcp.0b013e3182825bce","type":"journal-article","created":{"date-parts":[[2013,2,15]],"date-time":"2013-02-15T08:47:44Z","timestamp":1360918064000},"page":"162-169","source":"Crossref","is-referenced-by-count":32,"title":["Striatal and Extrastriatal Dopamine D2 Receptor Occupancy by a Novel Antipsychotic, Blonanserin"],"prefix":"10.1097","volume":"33","author":[{"given":"Amane","family":"Tateno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryosuke","family":"Arakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Okumura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Fukuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyoshi","family":"Honjo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichi","family":"Ishihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin-ichiro","family":"Kumita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiro","family":"Okubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-4-20210128","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2165\/11202620-000000000-00000","article-title":"Blonanserin: a review of its use in the management of schizophrenia.","volume":"24","author":"Deeks","year":"2010","journal-title":"CNS Drugs"},{"key":"R2-4-20210128","doi-asserted-by":"crossref","first-page":"615","DOI":"10.2165\/00023210-200923070-00006","article-title":". The efficacy and safety of blonanserin compared with haloperidol in acute-phase schizophrenia: a randomized, double-blind, placebo-controlled, multicentre study.","volume":"23","author":"Garcia","year":"2009","journal-title":"CNS Drugs"},{"key":"R3-4-20210128","first-page":"297","article-title":"Clinical evaluation of blonanserin for schizophrenia: a randomized study comparing blonanserin with risperidone.","volume":"11","author":"Miura","year":"2008","journal-title":"Jpn J Clin Psychopharmacol"},{"key":"R4-4-20210128","first-page":"158","article-title":". Pharmacological profile of AD-5423, a novel antipsychotic with both potent dopamine-D2 and serotonin-S2 antagonist properties.","volume":"264","author":"Oka","year":"1993","journal-title":"J Pharmacol Exp Ther"},{"key":"R5-4-20210128","first-page":"1263","article-title":"Pharmacological profile of blonanserin.","volume":"10","author":"Une","year":"2008","journal-title":"Jpn J Clin Psychopharmacol"},{"key":"R6-4-20210128","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1254\/fpj.132.351","article-title":". Pharmacological profiles and clinical effects of blonanserin (Lonasen) on schizophrenia.","volume":"132","author":"Ishibashi","year":"2008","journal-title":"Nihon Yakurigaku Zasshi"},{"key":"R7-4-20210128","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/WNF.0b013e3181dcda50","article-title":". Efficacy and tolerability of blonanserin in the patients with schizophrenia: a randomized, double-blind, risperidone-compared trial.","volume":"33","author":"Yang","year":"2010","journal-title":"Clin Neuropharmacol"},{"key":"R8-4-20210128","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.4088\/JCP.08m04307yel","article-title":". Positron emission tomography measurement of dopamine D2 receptor occupancy in the pituitary and cerebral cortex: relation to antipsychotic-induced hyperprolactinemia.","volume":"71","author":"Arakawa","year":"2010","journal-title":"J Clin Psychiatry"},{"key":"R9-4-20210128","doi-asserted-by":"crossref","first-page":"3111","DOI":"10.1038\/npp.2008.33","article-title":". Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and 18Ffallypride.","volume":"33","author":"Kegeles","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"R10-4-20210128","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1001\/archpsyc.1992.01820070032005","article-title":". Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects.","volume":"49","author":"Farde","year":"1992","journal-title":"Arch Gen Psychiatry"},{"key":"R11-4-20210128","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1176\/appi.ajp.157.4.514","article-title":". Relationship between dopamine D2 occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia.","volume":"157","author":"Kapur","year":"2000","journal-title":"Am J Psychiatry"},{"key":"R12-4-20210128","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/0006-3223(93)90288-O","article-title":". Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients.","volume":"33","author":"Nordstrom","year":"1993","journal-title":"Biol Psychiatry"},{"key":"R13-4-20210128","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1097\/JCP.0b013e3182214aad","article-title":". Dopamine D2 receptor occupancy and clinical effects: a systematic review and pooled analysis.","volume":"31","author":"Uchida","year":"2011","journal-title":"J Clin Psychopharmacol"},{"key":"R14-4-20210128","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.4088\/JCP.v65n1108","article-title":". Prevalence of hyperprolactinemia in schizophrenia: association with typical and atypical antipsychotic treatment.","volume":"65","author":"Montgomery","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"R15-4-20210128","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia.","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr Bull"},{"key":"R16-4-20210128","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/j.1440-1819.1995.tb01895.x","article-title":"Current topics in tardive dyskinesia in Japan.","volume":"49","author":"Inada","year":"1995","journal-title":"Psychiatry Clin Neurosci"},{"key":"R18-4-20210128","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1006\/nimg.1998.0401","article-title":". Mapping of central D2 dopamine receptors in man using 11Craclopride: PET with an anatomic standardization technique.","volume":"9","author":"Ito","year":"1999","journal-title":"Neuroimage"},{"key":"R19-4-20210128","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1006\/nimg.1999.0502","article-title":". PET mapping of extrastriatal D2-like dopamine receptors in the human brain using an anatomic standardization technique and 11CFLB 457.","volume":"10","author":"Okubo","year":"1999","journal-title":"Neuroimage"},{"key":"R20-4-20210128","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1006\/nimg.2000.0717","article-title":". Error analysis for quantification of 11CFLB 457 binding to extrastriatal D2 dopamine receptors in the human brain.","volume":"13","author":"Ito","year":"2001","journal-title":"Neuroimage"},{"key":"R21-4-20210128","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1006\/nimg.1996.0066","article-title":"Simplified reference tissue model for PET receptor studies.","volume":"4","author":"Lammertsma","year":"1996","journal-title":"Neuroimage"},{"key":"R22-4-20210128","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1017\/S1461145799001431","article-title":". Extrastriatal dopamine D2 receptor density and affinity in the human brain measured by 3D PET.","volume":"2","author":"Suhara","year":"1999","journal-title":"Int J Neuropsychopharmacol"},{"key":"R23-4-20210128","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1038\/sj.jcbfm.9600493","article-title":". Consensus nomenclature for in vivo imaging of reversibly binding radioligands.","volume":"27","author":"Innis","year":"2007","journal-title":"J Cereb Blood Flow Metab"},{"key":"R24-4-20210128","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1017\/S1461145703003912","article-title":". Estimation of the time-course of dopamine D2 receptor occupancy in living human brain from plasma pharmacokinetics of antipsychotics.","volume":"7","author":"Takano","year":"2004","journal-title":"Int J Neuropsychopharmacol"},{"key":"R25-4-20210128","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.pnpbp.2005.06.011","article-title":". Time course of dopamine D2 receptor occupancy by clozapine with medium and high plasma concentrations.","volume":"30","author":"Takano","year":"2006","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R26-4-20210128","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s002130000643","article-title":". Dose relationship of limbic-cortical D2-dopamine receptor occupancy with risperidone.","volume":"154","author":"Yasuno","year":"2001","journal-title":"Psychopharmacology (Berl)"},{"key":"R27-4-20210128","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1001\/archpsyc.1990.01810150013003","article-title":". D2 dopamine receptors in neuroleptic-naive schizophrenic patients. A positron emission tomography study with 11Craclopride.","volume":"47","author":"Farde","year":"1990","journal-title":"Arch Gen Psychiatry"},{"key":"R28-4-20210128","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1001\/archpsyc.59.1.25","article-title":". Decreased dopamine D2 receptor binding in the anterior cingulated cortex in schizophrenia.","volume":"59","author":"Suhara","year":"2005","journal-title":"Arch Gen Psychiatry"},{"key":"R29-4-20210128","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1017\/S1461145703003699","article-title":". Decreased thalamic D2D3 receptor binding in drug-naive patients with schizophrenia: a PET study with 11CFLB 457.","volume":"6","author":"Talvik","year":"2003","journal-title":"Int J Neuropsychopharmacol"},{"key":"R30-4-20210128","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1176\/ajp.156.6.869","article-title":". Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients.","volume":"156","author":"Nyberg","year":"1999","journal-title":"Am J Psychiatry"},{"key":"R31-4-20210128","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1007\/s00228-010-0834-1","article-title":". Effect of dose timing in relation to food intake on systemic exposure to blonanserin.","volume":"66","author":"Saruwatari","year":"2010","journal-title":"Eur J Clin Pharmacol"},{"key":"R32-4-20210128","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s00213-007-1029-z","article-title":". Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia.","volume":"197","author":"Arakawa","year":"2008","journal-title":"Psychopharmacology (Berl)"},{"key":"R33-4-20210128","first-page":"1275","article-title":". Carbon-11-FLB 457: a radioligand for extrastriatal D2 dopamine receptors.","volume":"36","author":"Halldin","year":"1995","journal-title":"J Nucl Med"},{"key":"R34-4-20210128","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0893-133X(97)00112-7","article-title":"Do novel antipsychotics have similar pharmacological characteristics A review of the evidence.","volume":"18","author":"Arnt","year":"1998","journal-title":"Neuropsychopharmacology"},{"key":"R35-4-20210128","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1038\/sj.npp.1301242","article-title":". Striatal vs extrastriatal dopamine D2 receptors in antipsychotic responsea double-blind PET study in schizophrenia.","volume":"32","author":"Agid","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"R36-4-20210128","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1038\/sj.npp.1300836","article-title":". Occupancy of striatal and extrastriatal dopamine D2D3 receptors by olanzapine and haloperidol.","volume":"30","author":"Kessler","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"R37-4-20210128","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1038\/sj.npp.1301108","article-title":". Occupancy of striatal and extrastriatal dopamine D2 receptors by clozapine and quetiapine.","volume":"31","author":"Kessler","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"R38-4-20210128","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/syn.890200303","article-title":". Variability in D2-dopamine receptor density and affinity: a PET study with 11Craclopride in man.","volume":"20","author":"Farde","year":"1995","journal-title":"Synapse"},{"key":"R39-4-20210128","first-page":"1064","article-title":"Regional selectivity in clozapine treatment Am J Psychiatry.","volume":"159","author":"Kessler","year":"2002","journal-title":""},{"key":"R40-4-20210128","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1017\/S1461145708009577","article-title":". No regional difference in dopamine D2 receptor occupancy by the second-generation antipsychotic drug risperidone in humans: a positron emission tomography study.","volume":"12","author":"Ito","year":"2009","journal-title":"Int J Neuropsychopharmacol"},{"key":"R41-4-20210128","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/syn.20813","article-title":". Positron emission tomography imaging of dopamine D2D3 receptors in the human cortex with 11CFLB 457: reproducibility studies.","volume":"65","author":"Narendran","year":"2011","journal-title":"Synapse"}],"container-title":["Journal of Clinical Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/JCP.0b013e3182825bce","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:00:57Z","timestamp":1620957657000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00004714-201304000-00004"}},"subtitle":["A PET Study With [11C]Raclopride and [11C]FLB 457 in Schizophrenia"],"short-title":[],"issued":{"date-parts":[[2013,4]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/jcp.0b013e3182825bce","relation":{},"ISSN":["0271-0749"],"issn-type":[{"value":"0271-0749","type":"print"}],"subject":[],"published":{"date-parts":[[2013,4]]}}}